Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib
- Author
- LA ROSEE, Paul1 ; HOLM-ERIKSEN, Susanne1 ; YAPING SHOU3 ; DUGAN, Margaret3 ; HEHLMANN, Ruediger1 ; OTTMANN, Oliver G2 ; HOCHHAUS, Andréas1 ; KONIG, Heiko1 ; HÄRTEL, Nicolai1 ; ERNST, Thomas1 ; DEBATIN, Julia1 ; MUELLER, Martin C1 ; ERBEN, Philipp1 ; BINCKEBANCK, Anja2 ; WUNDERLE, Lydia2
[1] III Medizinische Universitätsklinik, Medizinische Fakultàt Mannheim der Universitàt Heidelberg, Mannheim, Germany
[2] Medizinische Klinik II, Johann Wolfgang Goethe Universitàt, Frankfurt, Germany
[3] Novartis Pharmaceuticals, East Hanover, NJ, United States - Source
Haematologica (Roma). 2008, Vol 93, Num 5, pp 765-769, 5 p ; ref : 21 ref
- ISSN
- 0390-6078
- Scientific domain
- Hematology
- Publisher
- Haematologica, Pavia
- Publication country
- Italy
- Document type
- Article
- Language
- English
- Author keyword
- BCR-ABL CRKL nilotinib resistance
- Keyword (fr)
- Activité biologique Anticancéreux Chromosome C9 anormal Chromosome G22 anormal Chromosome Ph1 Gène hybride Gène onc cellulaire Homme Hématologie Imatinib Inhibiteur enzyme Leucémie aiguë myéloblastique Leucémie myéloïde chronique Nilotinib Non-specific serine/threonine protein kinase Protein-tyrosine kinase Protéine adaptatrice Résistance traitement Surveillance Traitement Translocation chromosomique Gène abl Gène bcr Protéine Crkl Protéine adaptatrice CrkL Aberration chromosomique Cancer Chromosome anormal Enzyme Hémopathie maligne Inhibiteur de la tyrosine kinase Syndrome myéloprolifératif Transferases
- Keyword (en)
- Biological activity Antineoplastic agent Abnormal chromosome C9 Abnormal chromosome G22 Philadelphia chromosome Hybrid gene C-Onc gene Human Hematology Imatinib Enzyme inhibitor Acute myelogenous leukemia Chronic myelogenous leukemia Nilotinib Non-specific serine/threonine protein kinase Protein-tyrosine kinase Adaptor protein Treatment resistance Surveillance Treatment Chromosome translocation Protein Crkl Adaptor protein CrkL Chromosomal aberration Cancer Abnormal chromosome Enzyme Malignant hemopathy Tyrosine kinase inhibitor Myeloproliferative syndrome Transferases
- Keyword (es)
- Actividad biológica Anticanceroso Cromosoma C9 anormal Cromosoma G22 anormal Cromosoma Ph1 Gen híbrido Gen onc celular Hombre Hematología Imatinib Inhibidor enzima Leucemia aguda mieloblástica Leucemia mieloidea crónica Nilotinib Non-specific serine/threonine protein kinase Protein-tyrosine kinase Proteína adaptadora Resistencia tratamiento Vigilancia Tratamiento Translocación cromosómica Proteína Crkl Aberración cromosómica Cáncer Cromosoma anormal Enzima Hemopatía maligna Inhibidor tyrosine kinase Mieloproliferativo síndrome Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B23 Medical genetics / 002B23B Chromosome aberrations
- Discipline
- Blood diseases Medical genetics
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20350839
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.3324/haematol.12186 
https://dx.doi.org/10.3324/haematol.12186
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.3324\/haematol.12186\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Haematologica (Roma)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Haematologica (Roma)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"93\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"765\";s:8:\"\u0000*\u0000epage\";s:3:\"769\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0390-6078\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"LA ROSEE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Paul\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:21:\"HOLM-ERIKSEN, Susanne\";i:1;s:11:\"YAPING SHOU\";i:2;s:15:\"DUGAN, Margaret\";i:3;s:18:\"HEHLMANN, Ruediger\";i:4;s:17:\"OTTMANN, Oliver G\";i:5;s:18:\"HOCHHAUS, Andr\u00e9as\";i:6;s:12:\"KONIG, Heiko\";i:7;s:16:\"H\u00c4RTEL, Nicolai\";i:8;s:13:\"ERNST, Thomas\";i:9;s:14:\"DEBATIN, Julia\";i:10;s:17:\"MUELLER, Martin C\";i:11;s:14:\"ERBEN, Philipp\";i:12;s:17:\"BINCKEBANCK, Anja\";i:13;s:15:\"WUNDERLE, Lydia\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib\";s:8:\"\u0000*\u0000place\";s:5:\"Pavia\";s:6:\"\u0000*\u0000pub\";s:13:\"Haematologica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.3324\/haematol.12186\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Haematologica (Roma)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Haematologica (Roma)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"93\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"765\";s:8:\"\u0000*\u0000epage\";s:3:\"769\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0390-6078\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"LA ROSEE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Paul\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:21:\"HOLM-ERIKSEN, Susanne\";i:1;s:11:\"YAPING SHOU\";i:2;s:15:\"DUGAN, Margaret\";i:3;s:18:\"HEHLMANN, Ruediger\";i:4;s:17:\"OTTMANN, Oliver G\";i:5;s:18:\"HOCHHAUS, Andr\u00e9as\";i:6;s:12:\"KONIG, Heiko\";i:7;s:16:\"H\u00c4RTEL, Nicolai\";i:8;s:13:\"ERNST, Thomas\";i:9;s:14:\"DEBATIN, Julia\";i:10;s:17:\"MUELLER, Martin C\";i:11;s:14:\"ERBEN, Philipp\";i:12;s:17:\"BINCKEBANCK, Anja\";i:13;s:15:\"WUNDERLE, Lydia\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib\";s:8:\"\u0000*\u0000place\";s:5:\"Pavia\";s:6:\"\u0000*\u0000pub\";s:13:\"Haematologica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.3324\/haematol.12186\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.3324\/haematol.12186\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Haematologica (Roma)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Haematologica (Roma)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"93\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"765\";s:8:\"\u0000*\u0000epage\";s:3:\"769\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0390-6078\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"LA ROSEE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Paul\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:21:\"HOLM-ERIKSEN, Susanne\";i:1;s:11:\"YAPING SHOU\";i:2;s:15:\"DUGAN, Margaret\";i:3;s:18:\"HEHLMANN, Ruediger\";i:4;s:17:\"OTTMANN, Oliver G\";i:5;s:18:\"HOCHHAUS, Andr\u00e9as\";i:6;s:12:\"KONIG, Heiko\";i:7;s:16:\"H\u00c4RTEL, Nicolai\";i:8;s:13:\"ERNST, Thomas\";i:9;s:14:\"DEBATIN, Julia\";i:10;s:17:\"MUELLER, Martin C\";i:11;s:14:\"ERBEN, Philipp\";i:12;s:17:\"BINCKEBANCK, Anja\";i:13;s:15:\"WUNDERLE, Lydia\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib\";s:8:\"\u0000*\u0000place\";s:5:\"Pavia\";s:6:\"\u0000*\u0000pub\";s:13:\"Haematologica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.3324\/haematol.12186\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Haematologica (Roma)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Haematologica (Roma)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"93\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"765\";s:8:\"\u0000*\u0000epage\";s:3:\"769\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0390-6078\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"LA ROSEE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Paul\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:21:\"HOLM-ERIKSEN, Susanne\";i:1;s:11:\"YAPING SHOU\";i:2;s:15:\"DUGAN, Margaret\";i:3;s:18:\"HEHLMANN, Ruediger\";i:4;s:17:\"OTTMANN, Oliver G\";i:5;s:18:\"HOCHHAUS, Andr\u00e9as\";i:6;s:12:\"KONIG, Heiko\";i:7;s:16:\"H\u00c4RTEL, Nicolai\";i:8;s:13:\"ERNST, Thomas\";i:9;s:14:\"DEBATIN, Julia\";i:10;s:17:\"MUELLER, Martin C\";i:11;s:14:\"ERBEN, Philipp\";i:12;s:17:\"BINCKEBANCK, Anja\";i:13;s:15:\"WUNDERLE, Lydia\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib\";s:8:\"\u0000*\u0000place\";s:5:\"Pavia\";s:6:\"\u0000*\u0000pub\";s:13:\"Haematologica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.3324\/haematol.12186\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Haematologica (Roma)\";s:9:\"\u0000*\u0000stitle\";s:20:\"Haematologica (Roma)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"93\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"765\";s:8:\"\u0000*\u0000epage\";s:3:\"769\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0390-6078\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"LA ROSEE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Paul\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:21:\"HOLM-ERIKSEN, Susanne\";i:1;s:11:\"YAPING SHOU\";i:2;s:15:\"DUGAN, Margaret\";i:3;s:18:\"HEHLMANN, Ruediger\";i:4;s:17:\"OTTMANN, Oliver G\";i:5;s:18:\"HOCHHAUS, Andr\u00e9as\";i:6;s:12:\"KONIG, Heiko\";i:7;s:16:\"H\u00c4RTEL, Nicolai\";i:8;s:13:\"ERNST, Thomas\";i:9;s:14:\"DEBATIN, Julia\";i:10;s:17:\"MUELLER, Martin C\";i:11;s:14:\"ERBEN, Philipp\";i:12;s:17:\"BINCKEBANCK, Anja\";i:13;s:15:\"WUNDERLE, Lydia\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib\";s:8:\"\u0000*\u0000place\";s:5:\"Pavia\";s:6:\"\u0000*\u0000pub\";s:13:\"Haematologica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
